Development of drugs for severe malaria in children

Area of Science:

• Global Health
• Infectious Diseases
• Pediatric Medicine

Background:

• Malaria disproportionately affects African children under five, causing over 90% of deaths.
• Current drug development often relies on adult trials, with extrapolations to pediatric dosing proving unreliable.
• Limited adult severe malaria cases hinder large-scale adult trials, delaying pediatric drug development.

Purpose of the Study:

• To propose an alternative drug development pathway for pediatric severe malaria.
• To address the challenges of conducting large-scale mortality trials in pediatric severe malaria patients.
• To optimize the development of safe and effective malaria treatments for young children.

Main Methods:

• Conduct small-scale adult severe malaria studies focusing on safety and efficacy using surrogate endpoints.
• Follow with small pilot studies in pediatric severe malaria using the same surrogate endpoints.
• Utilize adaptive designs and carefully selected interventions for large, powered Phase III pediatric trials with mortality endpoints.

Main Results:

• The proposed pathway prioritizes safety and efficacy in adults before pediatric testing.
• Surrogate endpoints in adult severe malaria can provide crucial early data.
• This approach facilitates ethical and efficient progression to large pediatric trials.

Conclusions:

• An alternative drug development pathway using surrogate endpoints in adults can accelerate safe and effective malaria treatments for children.
• This strategy addresses the limitations of traditional trial designs in pediatric severe malaria.
• Careful ethical considerations and adaptive designs are crucial for successful implementation.